SCHEMBL6099362

SCHEMBL6099362

CCN1C(=O)C(=O)N(c2cc(Cl)ccc2C)C1=S

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 0.43
KMT2A Q03164 8/20 0.43
SMN1; SMN2 Q16637 1/20 0.39
ALDH1A1 P00352 3/20 0.39
USP2 O75604 2/20 0.39
KDM4E B2RXH2 1/20 0.39
LMNA P02545 1/20 0.39
HPGD P15428 1/20 0.39
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39
HSD17B10 Q99714 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
TNFRSF1A P19438 1/20 0.38
HTR1A P08908 1/20 0.38
ADRA1B P35368 1/20 0.38
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6097903 0.89 ALDH1A1 (0.39) MEN1KMT2ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL6097864 0.84 MEN1 (0.40) MEN1KMT2AALDH1A1USP2KDM4E
SCHEMBL6096783 0.83 PARK7 (0.46) MEN1KMT2ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL6095067 0.81 MEN1 (0.43) MEN1KMT2AALDH1A1USP2HTR1A
SCHEMBL8716448 0.75 KMT2A (0.64) MEN1KMT2ASMN1; SMN2ALDH1A1LMNA
SCHEMBL8585347 0.73 KMT2A (0.53) MEN1KMT2AALDH1A1USP2HTR1A
SCHEMBL6097313 0.73 KMT2A (0.45) MEN1KMT2ASMN1; SMN2ALDH1A1USP2
SCHEMBL11610302 0.73 NPSR1 (0.45) MEN1KMT2AALDH1A1HPGDL3MBTL1
SCHEMBL7163578 0.72 MEN1 (0.47) MEN1KMT2AALDH1A1USP2HTR1A
SCHEMBL6097897 0.71 NPC1 (0.44) MEN1KMT2ASMN1; SMN2ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7135492-B2 Increases the concentration of high density lipoprotein cholesterol in the blood; dyslipoproteinemia; angina pectoris, myocardial infarction, antiarrhythmia agents, heart failure, kidney failure stroke, peripheral arterial occulsion WYETH (US) 2006-11-14 US disclosed
US-20030119889-A1 1,3-Disubstituted-2- thioxo-imidazolidine-4,5-dione derivatives useful in the treatment of atherosclerosis WYETH 2003-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119889-A1 1,3-Disubstituted-2- thioxo-imidazolidine-4,5-dione derivatives useful in the treatment of atherosclerosis FFAR4, FFAR1, MSR1 MEN1 4454/4885KMT2A 3781/4885SMN1; SMN2 4084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.